

Supplementary Table 1. Demographic and clinical characteristics of liver transplant patients treated with TAC-based therapies by cirrhosis and HCC

		CIRRHOSIS								HCC							
		TAC+MMF		TAC MONO		TAC+mTOR		pvalue	pvalue	TAC+MMF		TAC MONO		TAC+mTOR		pvalue	pvalue
		296		307		64		TAC MONO vs TAC+ MMF	TAC+ mTOR vs TAC+ MMF	355		468		154		TAC MONO vs TAC+ MMF	TAC+ mTOR vs TAC+ MMF
		n	%	n	%	n	%			n	%	n	%	n	%		
Region	Veneto	62	20.9	69	22.5	30	46.9	**	**	32	9.0	88	18.8	87	56.5	**	**
	Lombardy	68	23.0	212	69.1	0	0.0			77	21.7	342	73.1	8	5.2		
	Latium	107	36.1	21	6.8	29	45.3			187	52.7	36	7.7	56	36.4		
	Sardinia	59	19.9	5	1.6	5	7.8			59	16.6	2	0.4	3	1.9		
Sex	M	206	69.6	223	72.6	51	79.7			325	91.5	415	88.7	130	84.4		*
	F	90	30.4	84	27.4	13	20.3			30	8.5	53	11.3	24	15.6		
Age	18-49	94	31.8	83	27.0	27	42.2		*	42	11.8	60	12.8	17	11.0		
	50-59	126	42.6	141	45.9	16	25.0			162	45.6	224	47.9	64	41.6		
	60+	76	25.7	83	27.0	21	32.8			151	42.5	184	39.3	73	47.4		
BMI	underweight	9	3.0	11	3.6	1	1.6			5	1.4	4	0.9	2	1.3		
	normal	136	45.9	148	48.2	26	40.6			146	41.1	192	41.0	64	41.6		
	overweight/obese	151	51.0	148	48.2	37	57.8			204	57.5	272	58.1	88	57.1		
Discharge	2009-2013	70	23.7	71	23.1	8	12.5		**	81	22.8	100	21.4	40	26.0		**
Year 2	2014-2016	122	41.2	126	41.1	17	26.6			127	35.8	179	38.2	31	20.1		
	2017-2019	104	35.1	110	35.8	39	60.9			147	41.4	189	40.4	83	53.9		
Hospital	standard (<15 days)	68	23.0	42	13.7	29	45.3	**	**	122	34.4	159	34.0	81	52.6		**
length	prolonged (≥15 days)	228	77.0	265	86.3	35	54.7			233	65.6	309	66.0	73	47.4		
Sex	M	152	51.4	181	59.0	37	57.8			206	58.0	268	57.3	99	64.3		
(donor)	F	144	48.6	126	41.0	27	42.2			149	42.0	200	42.7	55	35.7		
Age	<50	86	29.1	74	24.1	20	31.3			110	31.0	104	22.2	35	22.7	**	**
(donor)	50-59	50	16.9	63	20.5	11	17.2			67	18.9	79	16.9	16	10.4		
	60+	160	54.1	170	55.4	33	51.6			178	50.1	285	60.9	103	66.9		
Score	0-24	206	69.6	230	74.9	51	79.7			321	90.4	443	94.7	150	97.4	*	**
MELD ⁵	25+	90	30.4	77	25.1	13	20.3			34	9.6	25	5.3	4	2.6		
Charlson	0-1	182	61.5	208	67.8	38	59.4			8	2.3	40	8.5	8	5.2	**	
Index	2	92	31.1	80	26.1	19	29.7			221	62.3	318	67.9	102	66.2		
	3+	22	7.4	19	6.2	7	10.9			126	35.5	110	23.5	44	28.6		
Renal disease and dialysis		50	16.9	42	13.7	13	20.3			24	6.8	15	3.2	10	6.5	*	
Cardio-cerebrovascular diseases		47	15.9	42	13.7	10	15.6			64	18.0	65	13.9	20	13.0		
Respiratory diseases		56	18.9	57	18.6	12	18.8			52	14.6	65	13.9	21	13.6		
Cancer		17	5.7	21	6.8	5	7.8			11	3.1	7	1.5	3	1.9		
Thyroid disorders		32	10.8	19	6.2	1	1.6	*	*	20	5.6	11	2.4	5	3.2	*	
Diabetes		110	37.2	145	47.2	21	32.8	*		152	42.8	207	44.2	65	42.2		
Anaemia		158	53.4	122	39.7	35	54.7	**		120	33.8	115	24.6	47	30.5	**	
Infections		44	14.9	46	15.0	6	9.4			33	9.3	26	5.6	12	7.8	*	
Anticoagulants/Antiplatelet		34	11.5	45	14.7	7	10.9			67	18.9	97	20.7	31	20.1		
Diuretics		248	83.8	245	79.8	54	84.4			234	65.9	245	52.4	101	65.6	**	
LMAs		44	14.9	50	16.3	16	25.0		*	37	10.4	52	11.1	37	24.0		**

* p-value <0.0;

** p-value<0.01;

§ model for end-stage liver disease